SMB congratulates Khondrion on the start of the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes! For more information on the clinical trial please refer to the Press release from Khondrion.
“SMB vormt een belangrijke schakel in het Nijmeegse innovatienetwerk van bedrijven en universiteit”
Pieter Nieuwland, FutureChemistrySMB congratulates Khondrion on the start of the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes! For more information on the clinical trial please refer to the Press release from Khondrion.